

Bradford S Hoppe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3502657/publications.pdf>

Version: 2024-02-01

170
papers

3,795
citations

117625
34
h-index

155660
55
g-index

171
all docs

171
docs citations

171
times ranked

3580
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting—the MSKCC experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 691-702.	0.8	213
2	Acute Skin Toxicity Following Stereotactic Body Radiation Therapy for Stage I Non-Small-Cell Lung Cancer: Who's at Risk?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1283-1286.	0.8	169
3	Effective Dose Reduction to Cardiac Structures Using Protons Compared With 3DCRT and IMRT in Mediastinal Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 449-455.	0.8	126
4	Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 505-516.	0.8	125
5	Outcomes and Prognostic Variables in Adenoid Cystic Carcinoma of the Head and Neck: A Recent Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1365-1372.	0.8	122
6	Impaired T Helper 2 Response to Aeroallergen in Helminth-Infected Patients with Asthma. <i>Journal of Infectious Diseases</i> , 2004, 190, 1797-1803.	4.0	106
7	Five-Year Outcomes from 3 Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 596-602.	0.8	103
8	Early Outcomes From Three Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 213-221.	0.8	95
9	Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 422-434.	0.8	90
10	Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. <i>Blood</i> , 2018, 132, 1635-1646.	1.4	86
11	Patterns and Incidence of Neural Invasion in Patients With Cancers of the Paranasal Sinuses. <i>JAMA Otolaryngology</i> , 2009, 135, 173.	1.2	85
12	Unresectable Carcinoma of the Paranasal Sinuses: Outcomes and Toxicities. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 763-769.	0.8	82
13	Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. <i>Cancer</i> , 2014, 120, 1076-1082.	4.1	82
14	Proton Radiation Therapy Offers Reduced Normal Lung and Bone Marrow Exposure for Patients Receiving Dose-Escalated Radiation Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer: A Dosimetric Study. <i>Clinical Lung Cancer</i> , 2011, 12, 252-257.	2.6	75
15	Consolidative Involved-Node Proton Therapy for Stage IA-III B Mediastinal Hodgkin Lymphoma: Preliminary Dosimetric Outcomes From a Phase II Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 260-267.	0.8	72
16	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 652-669.	0.8	71
17	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 909-933.	0.8	67
18	Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. <i>Acta Oncologica</i> , 2013, 52, 498-505.	1.8	66

#	ARTICLE	IF	CITATIONS
19	Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. International Journal of Radiation Oncology Biology Physics, 2017, 99, 825-842.	0.8	66
20	Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: A dosimetric comparison with photon-based stereotactic body radiotherapy. Radiotherapy and Oncology, 2010, 97, 425-430.	0.6	63
21	Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1053-1059.	0.8	60
22	Complementation of the Radiosensitive M059J Cell Line. Radiation Research, 2000, 153, 125-130.	1.5	57
23	Protons offer reduced bone marrow, small bowel, and urinary bladder exposure for patients receiving neoadjuvant radiotherapy for resectable rectal cancer. Journal of Gastrointestinal Oncology, 2014, 5, 3-8.	1.4	56
24	Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer, 2012, 118, 4619-4626.	4.1	51
25	The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiation Therapy Era. Practical Radiation Oncology, 2020, 10, e147-e154.	2.1	51
26	Involved-Field Radiotherapy Before High-Dose Therapy and Autologous Stem-Cell Rescue in Diffuse Large-Cell Lymphoma: Long-Term Disease Control and Toxicity. Journal of Clinical Oncology, 2008, 26, 1858-1864.	1.6	50
27	Protons Offer Reduced Normal-Tissue Exposure for Patients Receiving Postoperative Radiotherapy for Resected Pancreatic Head Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 158-163.	0.8	49
28	A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study. International Journal of Radiation Oncology Biology Physics, 2016, 95, 517-522.	0.8	49
29	Improving Male Reproductive Health After Childhood, Adolescent, and Young Adult Cancer: Progress and Future Directions for Survivorship Research. Journal of Clinical Oncology, 2018, 36, 2160-2168.	1.6	48
30	Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: Technique, early outcomes, and toxicity. Head and Neck, 2008, 30, 925-932.	2.0	46
31	Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN. Radiotherapy and Oncology, 2018, 128, 44-55.	0.6	46
32	Hemorrhagic Radiation Cystitis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 331-336.	1.3	41
33	Rectal Toxicity After Proton Therapy For Prostate Cancer: An Analysis of Outcomes of Prospective Studies Conducted at the University of Florida Proton Therapy Institute. International Journal of Radiation Oncology Biology Physics, 2015, 91, 172-181.	0.8	41
34	Proton Therapy and Concomitant Capecitabine for Non-Metastatic Unresectable Pancreatic Adenocarcinoma. International Journal of Particle Therapy, 2014, 1, 692-701.	1.8	38
35	Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAH): Methodology statement. Pediatric Blood and Cancer, 2017, 64, e26421.	1.5	35
36	Proton Therapy With Concurrent Chemotherapy for Non-Small-Cell Lung Cancer: Technique and Early Results. Clinical Lung Cancer, 2012, 13, 352-358.	2.6	34

#	ARTICLE	IF	CITATIONS
37	Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer. <i>Acta Oncol</i> 2017, 56, 963-970.	1.8	31
38	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. <i>Blood</i> , 2020, 135, 2365-2374.	1.4	30
39	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.6	27
40	Protons Safely Allow Coverage of High-Risk Nodes for Patients with Regionally Advanced Non-Small-Cell Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2011, 10, 317-322.	1.9	25
41	Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer. <i>Acta Oncol</i> 2013, 52, 506-513.	1.8	25
42	Second tumor risk in children treated with proton therapy. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28941.	1.5	23
43	Comparison of Techniques for Involved-Site Radiation Therapy in Patients With Lower Mediastinal Lymphoma. <i>Practical Radiation Oncology</i> , 2019, 9, 426-434.	2.1	22
44	Expert Radiation Oncologist Interpretations of Involved-Site Radiation Therapy Guidelines in the Management of Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 40-45.	0.8	21
45	Hypofractionated Proton Therapy with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial from the University of Florida and Proton Collaborative Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 455-461.	0.8	21
46	Proton Radiotherapy for Prostate Cancer Is Not Associated With Post-Treatment Testosterone Suppression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1222-1226.	0.8	20
47	Proton Therapy for Pediatric Hodgkin Lymphoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1522-1526.	1.5	20
48	Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma. <i>JAMA Oncology</i> , 2019, 5, 689.	7.1	20
49	Cardiac sparing with proton therapy in consolidative radiation therapy for Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 1559-1562.	1.3	19
50	Radiation for Prostate Cancer: Intensity Modulated Radiation Therapy versus Proton Beam. <i>Journal of Urology</i> , 2015, 193, 1089-1091.	0.4	19
51	Proton therapy in the management of non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2608-2612.	1.3	19
52	Improving the Therapeutic Ratio by Using Proton Therapy in Patients With Stage I or II Seminoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 31-37.	1.3	18
53	Management of Radiation Proctitis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 517-523.	1.3	18
54	Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry. <i>Acta Oncol</i> 2016, 55, 1378-1380.	1.8	18

#	ARTICLE	IF	CITATIONS
55	Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: Results of two prospective trials. <i>Acta Oncol</i> ³ <i>gica</i> , 2013, 52, 463-469.	1.8	17
56	Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health. <i>Acta Oncol</i> ³ <i>gica</i> , 2018, 57, 582-588.	1.8	17
57	Radiation therapy related cardiac disease risk in childhood cancer survivors: Updated dosimetry analysis from the Childhood Cancer Survivor Study. <i>Radiotherapy and Oncology</i> , 2021, 163, 199-208.	0.6	17
58	ACR appropriateness Criteria [®] pediatric Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1305-1312.	1.5	16
59	ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. <i>Journal of the American College of Radiology</i> , 2014, 11, 1026-1033.e3.	1.8	16
60	ITV-Based Robust Optimization for VMAT Planning of Stereotactic Body Radiation Therapy of Lung Cancer. <i>Practical Radiation Oncology</i> , 2019, 9, 38-48.	2.1	16
61	Postoperative Proton Therapy in the Management of Stage III Thymoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, e38-e40.	1.1	15
62	Rationale and early outcomes for the management of thymoma with proton therapy. <i>Translational Lung Cancer Research</i> , 2018, 7, 106-113.	2.8	15
63	Comparing Breath Hold and Free Breathing during Intensity-Modulated Radiation Therapy and Proton Therapy in Patients with Mediastinal Hodgkin Lymphoma. <i>International Journal of Particle Therapy</i> , 2017, 3, 492-496.	1.8	15
64	Pulmonary Toxicity Following Proton Therapy for Thoracic Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 494-497.	0.8	14
65	Carbon ion radiation therapy in breast cancer: a new frontier. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 291-296.	2.5	14
66	Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression. <i>Acta Oncol</i> ³ <i>gica</i> , 2013, 52, 492-497.	1.8	13
67	Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2019-2024.	1.3	13
68	Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemotherapy and radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29212.	1.5	13
69	Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy. <i>Current Oncology Reports</i> , 2017, 19, 34.	4.0	12
70	Proton therapy for thymic malignancies: multi-institutional patterns-of-care and early clinical outcomes from the proton collaborative group and the university of Florida prospective registries. <i>Acta Oncol</i> ³ <i>gica</i> , 2019, 58, 1036-1040.	1.8	12
71	Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma. <i>Advances in Radiation Oncology</i> , 2017, 2, 197-203.	1.2	11
72	Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: An analysis of the National Cancer Database. <i>Radiotherapy and Oncology</i> , 2019, 138, 75-79.	0.6	11

#	ARTICLE	IF	CITATIONS
73	Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 500-506.	1.2	11
74	Radiation Therapy Across Pediatric Hodgkin Lymphoma Research Group Protocols: A Report From the Staging, Evaluation, and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL) Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , ,	0.8	11
75	Proton therapy for lung cancer. <i>Thoracic Cancer</i> , 2012, 3, 109-116.	1.9	10
76	Outcomes in men with large prostates ($\geq 60 \text{ cm}^3$) treated with definitive proton therapy for prostate cancer. <i>Acta Oncologica</i> , 2013, 52, 470-476.	1.8	10
77	Hip fractures and pain following proton therapy for management of prostate cancer. <i>Acta Oncologica</i> , 2013, 52, 486-491.	1.8	10
78	Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy. <i>Oncology</i> , 2012, 26, 456-9, 462-5.	0.5	10
79	Reduction of prostate intrafraction motion using gas-release rectal balloons. <i>Medical Physics</i> , 2012, 39, 5869-5873.	3.0	9
80	Proton therapy in a pediatric patient with stage III Hodgkin lymphoma. <i>Acta Oncologica</i> , 2013, 52, 592-594.	1.8	9
81	Salvage of Locally Recurrent Prostate Cancer After Definitive Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 411-416.	1.3	9
82	ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 610-620.	1.3	9
83	Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused Ultrasound. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 465-471.	0.8	9
84	Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors. <i>Advances in Radiation Oncology</i> , 2019, 4, 699-705.	1.2	9
85	Radiation-induced tumor immunity in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1605-1611.	1.9	9
86	Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 106-112.e1.	0.4	9
87	Consensus Statement on Proton Therapy for Prostate Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 1-16.	1.8	9
88	Proton therapy for prostate cancer. <i>Oncology</i> , 2011, 25, 644-50, 652.	0.5	9
89	Outcomes of Patients With Non-Hodgkin's Lymphoma Treated With Bexxar With or Without External-Beam Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1122-1127.	0.8	8
90	Androgen Deprivation Therapy and Definitive Radiotherapy for Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 530-534.	1.3	8

#	ARTICLE	IF	CITATIONS
91	Proton-based chemoradiation for synchronous bilateral non-small-cell lung cancers: A case report. Thoracic Cancer, 2013, 4, 198-202.	1.9	8
92	Does Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 261-265.	1.3	7
93	Expert consensus statements for Waldeyer's ring involvement in pediatric Hodgkin lymphoma: The staging, evaluation, and response criteria harmonization (SEARCH) for childhood, adolescent, and young adult Hodgkin lymphoma (CAYAHL) group. Pediatric Blood and Cancer, 2020, 67, e28361.	1.5	7
94	Development and validation of an age-scalable cardiac model with substructures for dosimetry in late-effects studies of childhood cancer survivors. Radiotherapy and Oncology, 2020, 153, 163-171.	0.6	7
95	Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. International Journal of Radiation Oncology Biology Physics, 2021, 109, 220-230.	0.8	7
96	Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2022, 112, 158-166.	0.8	7
97	Estimating the Number of Patients Eligible for Carbon Ion Radiotherapy in the United States. International Journal of Particle Therapy, 2020, 7, 31-41.	1.8	7
98	Sperm preservation and neutron contamination following proton therapy for prostate cancer study. Acta Oncol ³ gica, 2017, 56, 17-20.	1.8	6
99	Image-guided hypofractionated double-scattering proton therapy in the management of centrally-located early-stage non-small cell lung cancer. Acta Oncol ³ gica, 2020, 59, 1164-1170.	1.8	6
100	A comparative study of prostate PTV margins for patients using hydrogel spacer or rectal balloon in proton therapy. Physica Medica, 2021, 81, 47-51.	0.7	6
101	Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue. Advances in Radiation Oncology, 2021, 6, 100714.	1.2	6
102	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. International Journal of Radiation Oncology Biology Physics, 2021, 111, 36-44.	0.8	6
103	Image-Guided Hypofractionated Proton Therapy in Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Study. International Journal of Particle Therapy, 2020, 7, 1-10.	1.8	6
104	Advancing the Therapeutic Index in Stage III/IV Pediatric Hodgkin Lymphoma with Proton Therapy. International Journal of Particle Therapy, 2014, 1, 343-356.	1.8	6
105	Proton Therapy in the Management of Lymphoma. Cancer Journal (Sudbury, Mass), 2014, 20, 387-392.	2.0	5
106	Proton therapy in stage II-IV non-small cell lung cancer: pattern of care and impact on trial accrual. Acta Oncol ³ gica, 2018, 57, 692-693.	1.8	5
107	Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer. Cancer Investigation, 2019, 37, 85-89.	1.3	5
108	Patient-Reported Sexual Survivorship Following High-Dose Image-Guided Proton Therapy for Prostate Cancer. Radiotherapy and Oncology, 2019, 134, 204-210.	0.6	5

#	ARTICLE	IF	CITATIONS
109	Carbon Ion Radiotherapy in the Treatment of Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 737-743.	1.1	5
110	Cardiac MRI for Detecting Early Cardiac Toxicity after Proton Therapy for Hodgkin Lymphoma. <i>International Journal of Particle Therapy</i> , 2019, 5, 41-44.	1.8	5
111	Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 732-741.	0.8	5
112	A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome. <i>Blood Advances</i> , 2022, 6, 4241-4250.	5.2	5
113	Selective nodal irradiation of regionally advanced non-small cell lung cancer with proton therapy and IMRT: A dosimetric comparison. <i>Thoracic Cancer</i> , 2012, 3, 169-174.	1.9	4
114	When is Elective Pelvic Lymph Node Irradiation Indicated in Definitive Radiotherapy for Localized Prostate Cancer?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 644-647.	1.3	4
115	Proton therapy for Hodgkin lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 203-211.	2.3	4
116	ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 535-544.	1.3	4
117	Radiotherapy in Early-stage Gastric MALT. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 770-775.	1.3	4
118	Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radiology society appropriate use criteria. <i>Leukemia and Lymphoma</i> , 2021, 62, 1057-1065.	1.3	4
119	What men want: Results from a national survey on decision making for prostate cancer treatment and research participation. <i>Clinical and Translational Science</i> , 2021, 14, 2314-2326.	3.1	4
120	Carbon Ion Radiotherapy in the Management of Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1169-1179.	3.7	4
121	Patient-Reported Quality of Life in Men with Transurethral Resection of the Prostate Undergoing Proton Therapy for Management of Prostate Cancer. <i>International Journal of Particle Therapy</i> , 2016, 2, 518-524.	1.8	4
122	Bacterial Urinary Tract Infection after Transrectal Placement of Fiducial Markers prior to Proton Radiotherapy for Prostate Cancer. <i>International Journal of Particle Therapy</i> , 2016, 3, 21-26.	1.8	4
123	Survivor and Caregiver Expectations and Preferences Regarding Lung Cancer Treatment. <i>International Journal of Particle Therapy</i> , 2019, 6, 42-49.	1.8	4
124	Irradiating Residual Disease to 30 Gy with Proton Therapy in Pediatric Mediastinal Hodgkin Lymphoma. <i>International Journal of Particle Therapy</i> , 2020, 6, 11-16.	1.8	4
125	Evaluating Cardiac Biomarkers after Chemotherapy and Proton Therapy for Mediastinal Hodgkin Lymphoma. <i>International Journal of Particle Therapy</i> , 2017, 4, 35-38.	1.8	4
126	RE: Takatori K, Terashima K, Yoshida R, Horai A, Satake S, Ose T, Kitajima N, Kinoshita Y, Demizu Y, Fuwa N. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. <i>J Gastroenterol</i> . 2013; (E-pub only). <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, E33-4.	1.4	4

#	ARTICLE	IF	CITATIONS
127	Evaluating Disparities in Proton Radiation Therapy Use in AHOD1331, a Contemporary Children's Oncology Group Trial for Advanced-Stage Hodgkin Lymphoma. International Journal of Particle Therapy, 2022, 8, 55-57.	1.8	4
128	Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees. Frontiers in Oncology, 2021, 11, 748331.	2.8	4
129	ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology, 2013, 27, 786-94.	0.5	4
130	Real World Long-term Follow-up Experience with Yttrium-90Âbritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 618-625.	0.4	4
131	Targeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis. Blood, 0, , .	1.4	4
132	Consolidative Proton Therapy Following High-dose Chemotherapy and Autologous Stem Cell Transplant in an Adolescent with Relapsed Hodgkin Lymphoma. Journal of Adolescent and Young Adult Oncology, 2011, 1, 103-106.	1.3	3
133	ACR Appropriateness Criteria® Hodgkin Lymphomaâ€”Unfavorable Clinical Stage I and II. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 384-395.	1.3	3
134	Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clinical Cancer Research, 2018, 24, 3500-3509.	7.0	3
135	Controversies in proton therapy for prostate cancer. Chinese Clinical Oncology, 2016, 5, 55-55.	1.2	3
136	Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?. International Journal of Particle Therapy, 2020, 7, 13-20.	1.8	3
137	Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2022, 112, 890-900.	0.8	3
138	Carbon ion radiotherapy in the management of nonâ€small cell lung cancer. Precision Radiation Oncology, 2022, 6, 69-74.	1.1	3
139	Tomayto, tomahto: prescription dose and mean heart dose in evaluating the cardiac impact of involved-field radiation therapy for Hodgkin lymphoma survivors. Acta OncolÃ³gica, 2019, 58, 1783-1785.	1.8	2
140	Impact of unfavorable factors on outcomes among inoperable stage II-IV Nonsmall cell lung cancer patients treated with proton therapy. Acta OncolÃ³gica, 2019, 58, 313-319.	1.8	2
141	Long-Term Outcomes in 10-Year Survivors of Early-Stage Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 522-529.	0.8	2
142	Patient preferences for reducing bowel adverse events following prostate radiotherapy. PLoS ONE, 2020, 15, e0235616.	2.5	2
143	Impact of Detecting Occult Pathologic Nodal Disease During Resection for Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2020, 21, e274-e285.	2.6	2
144	Bacterial Urinary Tract Infection after Fiducial Marker Placement or Prostate Biopsy. International Journal of Particle Therapy, 2014, 1, 745-758.	1.8	2

#	ARTICLE	IF	CITATIONS
145	Race Does Not Affect Tumor Control, Adverse Effects, or Quality of Life after Proton Therapy. International Journal of Particle Therapy, 2017, 3, 461-472.	1.8	2
146	Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report. Journal of Cancer Education, 2023, 38, 201-205.	1.3	2
147	ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. Oncology, 2016, 30, 1099-103, 1106-8.	0.5	2
148	Rectal Culture and Sensitivity Analysis for Reducing Sepsis Risk After Fiducial Marker Placement. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1243-1245.	1.3	1
149	Stereotactic Ablative Body Radiotherapy for Primary Non-Small-Cell Lung Cancer: Achieving Local Control with a Lower Biologically Effective Dose. Cancer Investigation, 2018, 36, 289-295.	1.3	1
150	A positive approach: advances in proton therapy for the treatment of mediastinal lymphoma. Expert Review of Hematology, 2020, 13, 197-200.	2.2	1
151	Promising long-term results with proton therapy for localized prostate cancer. Nature Reviews Urology, 2021, 18, 137-138.	3.8	1
152	Pulmonary dose tolerance in hemithorax radiotherapy for Ewing sarcoma of the chest wall: Are we overestimating the risk of radiation pneumonitis?. Pediatric Blood and Cancer, 2021, 68, e29287.	1.5	1
153	Patient-reported quality of life in men with TURP undergoing proton therapy for prostate cancer.. Journal of Clinical Oncology, 2013, 31, 220-220.	1.6	1
154	Testosterone Replacement Therapy in Men with Prostate Cancer after Proton Therapy. International Journal of Particle Therapy, 2014, 1, 682-691.	1.8	1
155	Pulmonary Function after Proton Therapy for Hodgkin Lymphoma. International Journal of Particle Therapy, 2019, 5, 1-4.	1.8	1
156	Utilization of Radiation for Pediatric Hodgkin Lymphoma. Pediatric Oncology, 2018, , 313-341.	0.5	1
157	Principles of Radiation Therapy for Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 171-197.	0.2	1
158	Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer. Acta Oncologica, 2022, 61, 468-477.	1.8	1
159	In Reply to Dr. Lo et al.. International Journal of Radiation Oncology Biology Physics, 2009, 74, 978.	0.8	0
160	Re: Radiation for Prostate Cancer: Intensity Modulated Radiation Therapy versus Proton Beam. Journal of Urology, 2015, 194, 1507-1509.	0.4	0
161	Letter to the editor in response to Hopper et al., "Salvage image guided radiation therapy to the prostate after cryotherapy failure". Advances in Radiation Oncology, 2018, 3, 469.	1.2	0
162	Mediastinal Lymphoma. Practical Guides in Radiation Oncology, 2018, , 369-380.	0.1	0

#	ARTICLE	IF	CITATIONS
163	Follow Your Heart. International Journal of Radiation Oncology Biology Physics, 2020, 106, 17-18.	0.8	0
164	Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy. International Journal of Particle Therapy, 2021, 7, 52-64.	1.8	0
165	Comparative Effectiveness of Proton Therapy versus Photon Radiotherapy in Adolescents and Young Adults for Classical Hodgkin Lymphoma. International Journal of Particle Therapy, 2022, 8, 21-27.	1.8	0
166	Relapsed and Primary Refractory Diffuse Large B-Cell Lymphoma: Improving Outcome by Incorporating Involved Field Radiotherapy into a Comprehensive Second-Line High-Dose Therapy Strategy.. Blood, 2007, 110, 1893-1893.	1.4	0
167	Proton Therapy for Hodgkin Lymphoma. , 2011, , 197-203.		0
168	First report of a prospective trial of proton therapy and concomittant capecitabine for patients with nonmetastatic unresectable pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, e15223-e15223.	1.6	0
169	Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity. Value in Health, 2021, 25, 171-177.	0.3	0
170	Utilization and Cost Effectiveness of First-Line Yttrium-90 Ibritumomab Tiuxetan in Low-Grade Follicular and Marginal Zone Lymphomas Compared to Standard of Care Bendamustine Plus Rituximab: A Real-World Experience. Blood, 2021, 138, 4020-4020.	1.4	0